Why the study?
The 2021 ESC guidelines downgraded the recommendation for vasodilators in acute heart failure from IIa to IIb, prompting a summary of the evidence underlying this change.
Should vasodilators be used in the treatment of patients with acute heart failure?
Should vasodilators be used in the treatment of patients with acute heart failure?
This review summarizes the evidence supporting the 2021 ESC guideline downgrade of vasodilators for acute heart failure from a class IIA to IIB recommendation.
Answers are grounded in this paper and cite their sources.
Generally avoid vasodilators in AHF; leaves open need for targeted trials to refine selective use.
The 2021 European Society of Cardiolgoy (ESC) guidelines have downgraded the level of recommendation for the use of vasodilators in the treatment of patients with acute heart failure (AHF) from an IIA (‘should be considered') to IIB (‘may be considered’), indicating that patients with AHF such as this 68-year-old gentleman should in general NOT be treated with a vasodilator. In this review, we briefly summarize the evidence underlying this recommendation.
No takes yet. Share an insight, caveat, or question.
Mueller et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: